Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:PMN NASDAQ:SNYR NASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.76+4.0%$0.86$0.52▼$4.85$8.38M0.12593,939 shs56,550 shsPMNPromis Neurosciences$0.54+2.7%$0.59$0.38▼$1.59$27.97M-0.05614,560 shs144,805 shsSNYRSynergy CHC$2.42+14.2%$3.23$1.30▼$10.00$22.85MN/A92,685 shs217,585 shsTENXTenax Therapeutics$5.99+1.0%$5.96$3.25▼$7.89$27.31M1.4415,702 shs10,065 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics0.00%+17.64%+13.28%-31.62%-83.62%PMNPromis Neurosciences0.00%+0.75%-29.56%+12.71%-60.48%SNYRSynergy CHC0.00%-17.69%-27.98%+37.50%+2,320.00%TENXTenax Therapeutics0.00%-0.17%-3.70%-1.48%+50.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics1.6216 of 5 stars0.05.00.04.70.60.80.6PMNPromis Neurosciences3.1496 of 5 stars3.55.00.00.03.30.80.6SNYRSynergy CHC4.3015 of 5 stars3.80.00.00.03.13.33.1TENXTenax Therapeutics1.7346 of 5 stars3.61.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/APMNPromis Neurosciences 3.00Buy$4.33702.62% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00313.22% UpsideTENXTenax Therapeutics 3.25Buy$17.00183.81% UpsideCurrent Analyst Ratings BreakdownLatest BCLI, PMN, SNYR, and TENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.007/23/2025BCLIBrainstorm Cell TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy7/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.007/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ASNYRSynergy CHC$34.83M0.66$0.27 per share9.10($1.91) per share-1.27TENXTenax TherapeuticsN/AN/AN/AN/A$26.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$3.10N/AN/AN/AN/AN/A-519.50%11/13/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)SNYRSynergy CHC$2.12M$0.386.374.10N/A10.02%-18.56%20.28%N/ATENXTenax Therapeutics-$17.60M-$0.92N/AN/AN/AN/A-31.34%-30.39%11/12/2025 (Estimated)Latest BCLI, PMN, SNYR, and TENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17$10.80 million$6.74 million8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/A8/13/2025Q2 2025TENXTenax Therapeutics-$0.50-$0.27+$0.23-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21PMNPromis NeurosciencesN/A0.970.97SNYRSynergy CHCN/A2.742.41TENXTenax TherapeuticsN/A41.8941.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%PMNPromis Neurosciences50.13%SNYRSynergy CHCN/ATENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%PMNPromis Neurosciences6.11%SNYRSynergy CHC56.60%TENXTenax Therapeutics3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionablePMNPromis Neurosciences551.81 million48.64 millionNot OptionableSNYRSynergy CHC409.44 million4.10 millionN/ATENXTenax Therapeutics94.56 million4.39 millionNot OptionableBCLI, PMN, SNYR, and TENX HeadlinesRecent News About These CompaniesTenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025August 28, 2025 | globenewswire.comTenax Posts Wider Loss in Fiscal Q2August 14, 2025 | aol.comATenax Therapeutics reports Q2 EPS (27c), consensus (45c)August 14, 2025 | msn.comTenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comTENX Tenax Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comTenax Therapeutics Inc.May 9, 2025 | barrons.comTenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsApril 16, 2025 | seekingalpha.comTenax Therapeutics files to sell 4.14M shares of common stock for holdersApril 16, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTenax Therapeutics reports Q4 EPS (18c), consensus (43c)March 27, 2025 | markets.businessinsider.comTenax Therapeutics (TENX) Gets a Buy from William BlairMarch 27, 2025 | markets.businessinsider.comTenax Therapeutics: Q4 Earnings SnapshotMarch 25, 2025 | timesunion.comTTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comTenax Therapeutics Inc TENXMarch 14, 2025 | morningstar.comMRoth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)March 6, 2025 | markets.businessinsider.comTenax Therapeutics expands Phase 3 LEVEL program for TNX-103March 5, 2025 | markets.businessinsider.comTenax Therapeutics prices 378,346 shares at $6.04 in private placementMarch 5, 2025 | markets.businessinsider.comTenax Therapeutics Announces $25 Million Private PlacementMarch 5, 2025 | globenewswire.comTenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEFMarch 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, PMN, SNYR, and TENX Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$0.76 +0.03 (+3.97%) As of 08/29/2025 03:57 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Promis Neurosciences NASDAQ:PMN$0.54 +0.01 (+2.74%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.55 +0.01 (+1.32%) As of 08/29/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Synergy CHC NASDAQ:SNYR$2.42 +0.30 (+14.15%) As of 08/29/2025 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.Tenax Therapeutics NASDAQ:TENX$5.99 +0.06 (+1.01%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$5.96 -0.03 (-0.52%) As of 08/29/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
